{"id":"mepacrine","brandName":"mepacrine","genericName":"mepacrine","companyId":"unknown","companyName":"","phase":"unknown","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":1,"mechanism":{"target":"Aldehyde oxidase, Major prion protein, 5-hydroxytryptamine receptor 2A"},"administration":{},"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":["NCT00417274","NCT00574483","NCT01844076","NCT01839955","NCT00104663","NCT00183092"],"indications":{"approved":[{"name":"Giardiasis","diseaseId":"giardiasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT00417274","phase":"Phase 2","title":"An Open-Label, Phase II Safety, Tolerability, Drug Level and Efficacy Trial of Quinacrine in Patients With Androgen-Independent Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Cleveland BioLabs","isPivotal":false,"enrollment":31,"indication":"Prostatic Cancer","completionDate":"2008-05"},{"nctId":"NCT00574483","phase":"Phase 2","title":"An Open-label, Fixed-dose, Clinical Study of Quinacrine Safety and Efficacy in the Treatment of Advanced Renal Cell Carcinoma","status":"WITHDRAWN","sponsor":"Cleveland BioLabs","isPivotal":false,"enrollment":0,"indication":"Renal Cell Carcinoma","completionDate":"2008-01"},{"nctId":"NCT01844076","phase":"Phase 1","title":"Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma:A Phase I/II Investigator-Initiated Clinical Trial","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","isPivotal":false,"enrollment":19,"indication":"Colorectal Adenocarcinoma","completionDate":"2019-08-09"},{"nctId":"NCT01839955","phase":"Phase 1","title":"A Phase I Study of Erlotinib in Combination With Quinacrine in Patients With Advanced Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Neelesh Sharma MD PhD","isPivotal":false,"enrollment":12,"indication":"Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer","completionDate":"2016-10"},{"nctId":"NCT00104663","phase":"NA","title":"PRION-1: Quinacrine for Human Prion Disease. A Partially Randomized Patient Preference Trial to Evaluate the Activity and Safety of Quinacrine in Human Prion Disease","status":"COMPLETED","sponsor":"Medical Research Council","isPivotal":false,"enrollment":160,"indication":"Prion Disease","completionDate":"2007-03"},{"nctId":"NCT00183092","phase":"Phase 2","title":"Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease","status":"COMPLETED","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":69,"indication":"Creutzfeldt-Jakob Disease","completionDate":"2012-06"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}